Outsourcing

Articles

Contract manufacturers are making strategic partnerships and expanding services in the last quarter of 2019.

Developments in the Biopharmaceutical Outsourcing Industry

CDMOs are adding facilities and services to their portfolios in anticipation of the biologics industry’s continued growth.

Biologics Continue to Grow and Create Outsourcing Opportunities

The increasing growth in the cell- and gene-therapy markets is inspiring CDMOs to expand their services in this emerging biologic drug arena. 

Gene Therapies Propel Outsourcing Investment

Ronald A. Rader is senior director, Technical Research, at BioPlan Associates.

FDA inspections can create uncertainty. Supervision of the contract manufacturer 
is crucial in ensuring compliance. 


Bioprocessing Facilities and FDA Inspection Problems

Eric Langer has over 25 years experience in biotechnology and life sciences strategic marketing management, market research, and publishing. He has held senior management and marketing positions at biopharmaceutical supply companies. He has published and authored many books and reports on topics in Biotechnology, Large-scale BioManufacturing, and bioscience commercialization and communication. He teaches at Johns Hopkins University marketing management, biotech marketing, services marketing, and marketing in a regulated environment. In 1989 he co-founded BioPlan Associates, Inc. to provide market analysis, and strategy to biotech and healthcare organizations.

Ilene Roizman is communications manager at BioPlan Associates. 

Single-use systems can be a cost savings for CMOs, and these savings can be passed on to clients and, ultimately, to patients.

CMOs Leading the Way on Single-Use Systems Adoption

Outsourcing of manufacturing activities is expected to increase in 2019.

The Outlook for CMO Outsourcing in 2019

The growth in adoption of single-use systems for commercial manufacturing will be dramatic in coming years.

Single-Use Bioprocessing Equipment Trends and Adoption by CMOs

Partnerships, mergers, and new services indicate that biologics are continuing to influence CMOs’ and CDMOs’ decisions to expand their biopharmaceutical services.

Biopharma Demand Continues to Influence CMO Actions

This article highlights 15 years of changes in biopharmaceutical manufacturing.

Fifteen Years of Progress: Biopharmaceutical Industry Survey Results

New and expanded facilities point to the continuing growth of the biopharmaceutical industry.

Perspectives on Outsourcing